Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

Nautilus Biotechnolgy, Inc. Common Stock

NAUT

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.

Last trade $2.37
Day change +$0.265 (+12.62%)
Day range $2.10 – $2.44
Volume 3,187,687
Market cap $267M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$267.48M
Price / earnings
—
Price / book
2.29×
Price / sales
630.85×
EV / sales
606.17×
EV / EBITDA
-4.1×

Profitability

Earnings per share
-$0.46
Return on assets
-39.34%
Return on equity
-50.26%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
9.25×
Quick ratio
9.25×
Cash ratio
1.07×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$55.14M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NAUT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$234K$190K$0$0$0$0$0$0
Cost of revenue$24K$15K$0$0$0$0$0$0
Gross profit$210K$175K$0$0$0$0$0$0
Selling, general and administrative$6.77M$6.33M$6.42M$5.85M$5.87M$6.7M$7.31M$7.16M
Research and development$10.18M$9.61M$9.71M$9.58M$9.61M$10.39M$11.54M$12.82M
Total operating expenses$16.95M$15.94M$16.12M$15.42M$15.47M$17.1M$18.84M$19.98M
Operating income-$16.74M-$15.76M-$16.12M-$15.42M-$15.47M-$17.1M-$18.84M-$19.98M
Interest expense$1.17M$1.31M$1.44M$0$1.9M$2.08M$2.23M$0
Income before taxes-$15.64M-$14.47M-$14.7M-$13.78M-$13.57M-$15.03M-$16.61M-$17.59M
Income taxes$0$0$0$0$0$0$0$0
Net income-$15.64M-$14.47M-$14.7M-$13.78M-$13.57M-$15.03M-$16.61M-$17.59M
Net income attributable to common shareholders-$15.64M-$14.47M-$14.7M-$13.78M-$13.57M-$15.03M-$16.61M-$17.59M
EBITDA-$16.46M-$15.49M-$15.79M-$15.02M-$15.05M-$16.64M-$18.38M-$19.46M
Basic earnings per share-$0.12-$0.11-$0.12-$0.11-$0.11-$0.12-$0.13-$0.14
Diluted earnings per share-$0.12-$0.11-$0.12-$0.11-$0.11-$0.12-$0.13-$0.14

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Nautilus Biotechnology Reports Third Quarter 2026 Financial Results

Nautilus Biotechnology reported Q3 2026 revenue of $0.2 million and net loss of $15.6 million. The company published research in Nature Methods demonstrating its Iterative Mapping technology, shared early oncology proteoform assay data, and announced participation in an ARPA-H-funded SEEDS consortium with up to $6 million in expected funding to measure proteoforms in Alzheimer's disease and cancer research.

GlobeNewswire Inc.

Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium

Nautilus Biotechnology announced it will receive up to $6 million as part of a $51.7 million ARPA-H-funded SEEDS consortium led by Buck Institute and Georgetown University. The consortium aims to predict protein misfolding and develop diagnostics and therapeutics for neurodegenerative diseases and cancer. Nautilus will deploy its Voyager Platform to measure proteoforms in Alzheimer's disease and Ewing sarcoma research.

GlobeNewswire Inc.

Nautilus Biotechnology Reports First Quarter 2024 Financial Results

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.